45 signals · bluesky, h1b_lca, News / RSS
Scores are directional signals derived from aggregated public data — not verified findings or investment advice. Methodology
Signal-based estimates from public data — not verified assessments. Learn more
Some stress signals present but below significant thresholds.
Low risk signals — no significant operational or reputational pressure detected.
Auto-generated from public signals — AI summary pending. Based on 4 recent signals.
Bernstein raises Gilead Sciences stock price target on strong growth Investing.com
Gilead Sciences Price Target Raised to $195.00/Share From $175.00 by UBS Moomoo
Gilead Sciences, Inc. Stock 12‑Month Price Target Raised to $172.6, Implies 4% Upside TradingView
Biopharmaceutical focused on antiviral drugs.
Based on 45 signals across 3 sources · snapshot 4 Nov 2026
Strong: enough recent evidence to trust this score.
Overall community sentiment for Gilead Sciences is positive based on public signals as of 4 Nov 2026.
Based on 45 signals across 3 sources
Scores are directional signals derived from public data — not certified assessments or recommendations. Confidence indicates data coverage, not accuracy. Learn how scores are calculated →
Derived from public sources such as news, filings, and reported events.
Stock 12‑Month Price Target Raised to $172.6, Implies 4% Upside TradingView